Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

By W. Holman, Rury R. Jones, Nigel P. Kravitz, Barbara G. Lachin. New England Journal of Medicine, 2006

3,074 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1ddbbcfe5538964fea508f3d937b2b29c57e8689

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, result): “Glyburide had results superior to those of the other two drugs in the first year of treatment, but after 5 years, the group receiving it had the highest blood sugars (Kahn et al., 2006).”
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009, methodology): “The TZDs appear to have a more durable effect on glycemic control, particularly compared with sulfonylureas (55).”
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations (2011, background): “From our primary searches, we identified 140 RCTs and 26 observational studies in 166 articles that met inclusion criteria.”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “• The insulin-secretagogue SFUs have relatively potent A1C-lowering effects but lack durability and are associated with weight gain and hypoglycemia (84,115).”
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “Recognised side effects of TZDs include weight gain, fluid retention leading to oedema and/or heart failure in predisposed individuals and increased risk of bone fractures [57, 60].”
Cardiac Metabolism and Its Interactions with Contraction, Growth, and Survival of the Cardiomyocte (2013, result): “trial, as compared with cohorts treated with glyburide or metformin.(160) In the Prospective Pioglitazone Clinical Trial”
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “While monotherapy with the thiazolidinedione (TZD) rosiglitazone produces more long-lasting glycemic control compared to metformin or glyburide therapy (28), the edema, weight gain, risk of congestive heart failure (CHF), increased risk of fractures (29,30) and inconsistent data regarding myocardial”